Fractyl Health Inc. has announced the issuance of two new U.S. patents, further reinforcing its leadership in duodenal resurfacing applications. The patents, U.S. Patent No. 12,329,439 and U.S. Patent No. 12,303,185, focus on electrical energy ablation systems for treating tissue, particularly targeting the duodenal mucosa with various energy forms, including thermal and non-thermal electrical energy. These additions to Fractyl's intellectual property portfolio are designed to protect core innovations in metabolic disease treatment and reflect the company's ongoing commitment to advancing gut-targeted therapies.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.